PBISe, a novel selenium-containing drug for the treatment of malignant melanoma
Open Access
- 1 May 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (5), 1297-1308
- https://doi.org/10.1158/1535-7163.mct-07-2267
Abstract
Malignant melanoma is the most deadly form of skin cancer due to its highly metastatic nature. Untargeted therapies are ineffective for treating metastatic disease, leading to the development of agents specifically inhibiting proteins or pathways deregulated in melanoma. The deregulation of inducible nitric oxide synthase (iNOS) is one such event occurring in melanoma, and is correlated with poor survival. Current iNOS inhibitors, such as PBIT [S,S′-1,4-phenylenebis(1,2-ethanediyl)bis-isothiourea], require high concentrations for clinical efficacy causing systemic toxicity. To develop more potent agents effective at significantly lower concentrations, a novel isosteric analogue of PBIT was synthesized, called PBISe [S,S′-1,4-phenylenebis(1,2-ethanediyl)bis-isoselenourea], in which sulfur was replaced with selenium. PBISe kills melanoma cells >10-fold more effectively than PBIT, and cultured cancer cells are 2- to 5-fold more sensitive than normal cells. Like PBIT, PBISe targets iNOS but also has new inhibitory properties acting as an Akt3 pathway inhibitor and mitogen-activated protein kinase (MAPK) cascade activator, which causes decreased cancer cell proliferation and increased apoptosis. Inhibition of cellular proliferation mediated by PBISe induced a G2-M phase cell cycle block linked to excessively high MAPK activity causing decreased cyclin D1 and increased p21 as well as p27 levels. PBISe promotes apoptosis by inhibiting Akt3 signaling, elevating cleaved caspase-3 and PARP levels. Compared with PBIT, PBISe reduced tumor development by 30% to 50% in mice inducing a 2-fold increase in apoptosis with negligible associated systemic toxicity. Collectively, these results suggest that PBISe is a potent chemotherapeutic agent with novel properties enabling the targeting of iNOS, Akt3, and MAPK signaling, thereby promoting melanoma cell apoptosis and inhibition of proliferation. [Mol Cancer Ther 2008;7(5):1297–308]Keywords
This publication has 41 references indexed in Scilit:
- Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma DevelopmentCancer Research, 2008
- Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?Cancer Research, 2008
- Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and DiagnosisMayo Clinic Proceedings, 2007
- Targeting Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung MetastasesCancer Research, 2006
- BRAFE600-associated senescence-like cell cycle arrest of human naeviNature, 2005
- Functional and therapeutic significance of Akt deregulation in malignant melanomaCancer and Metastasis Reviews, 2005
- Nitric oxide signaling in colon cancer chemopreventionMutation Research, 2004
- Effect of selenium-enriched broccoli diet on differential gene expression in min mouse liver,The Journal of Nutritional Biochemistry, 2003
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Effect of dietary supplementation of selenite on pulmonary metastasis of melanoma cells in miceNutrition and Cancer, 1997